Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.
暂无分享,去创建一个
James X. Sun | K. Delman | D. Tyler | B. Coventry | A. Barbour | B. Smithers | M. Henderson | J. Zager | J. Serpell | P. Mosca | J. Farma | D. Speakman | G. Beasley | M. Lowe | J. Miura | A. Potdar | H. Daou | C. Farley | H. Kroon | J. Thompson | J. Teras | D. Mullen | Tim Kenyon-Smith | N. E. Farrow
[1] B. Coventry,et al. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] James X. Sun,et al. Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis , 2019, Annals of Surgical Oncology.
[3] D. Schadendorf,et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.
[4] R. Emerson,et al. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade , 2018, Cancer Immunology Research.
[5] M. Phelps,et al. Associations of High‐Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial , 2017, Clinical pharmacology and therapeutics.
[6] B. Coventry,et al. Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study , 2017, Annals of Surgical Oncology.
[7] A. Testori,et al. Diagnosis and treatment of in-transit melanoma metastases. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[8] David T. W. Jones,et al. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma , 2016, Oncotarget.
[9] P. Kam,et al. Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review , 2014, Journal of surgical oncology.
[10] P. Kam,et al. Isolated limb infusion: Technical aspects , 2014, Journal of surgical oncology.
[11] M. Dewhirst,et al. A multi‐institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan‐based isolated limb infusion , 2012, Cancer.
[12] S. Mocellin,et al. Systemic treatments for metastatic cutaneous melanoma. , 2014, The Cochrane database of systematic reviews.
[13] P. Kam,et al. Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. , 2011, Current problems in surgery.
[14] P. Kam,et al. Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution , 2011, Annals of Surgical Oncology.
[15] Merrick I Ross,et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Lane,et al. Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy , 2009, Cell cycle.
[18] M. Ross,et al. Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis , 2009, Annals of Surgical Oncology.
[19] M. Ross,et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. , 2009, Journal of the American College of Surgeons.
[20] P. Kam,et al. Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients , 2009, Annals of Surgical Oncology.
[21] C. Augustine,et al. Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity? , 2009, Annals of Surgical Oncology.
[22] B. Vrouenraets,et al. Isolated limb perfusion for melanoma. , 2008, Surgical oncology clinics of North America.
[23] R. Petersen,et al. Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.
[24] A. Hill,et al. Isolated limb infusion for melanoma. , 2007, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.
[25] H. Friedman,et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. , 2003, American journal of surgery.
[26] J. Thompson,et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy , 2001, Melanoma research.
[27] D. Freedman,et al. Body fat distribution and male/female differences in lipids and lipoproteins. , 1990, Circulation.
[28] E. V. van Slooten,et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.
[29] C. Verhoef,et al. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[30] D. Tyler,et al. Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma , 2014, Annals of Surgical Oncology.
[31] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[32] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .